Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry

The Lancet Haematology

Volumn 3, Issue 6, 2016, Pages e267-e275

  Riva, Nicoletta ^a   Ageno, Walter ^a   Schulman, Sam ^b   Beyer Westendorf, Jan ^c   Duce, Rita ^d   Malato, Alessandra ^e   Santoro, Rita ^f   Poli, Daniela ^g   Verhamme, Peter ^h   Martinelli, Ida ⁱ   Kamphuisen, Pieter ^j   Dentali, Francesco ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d GALLIERA HOSPITAL   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f PUGLIESE CIACCIO HOSPITAL   (Italy)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^j UNIVERSITY OF GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLEEDING; COHORT ANALYSIS; DISEASE REGISTRY; FEMALE; FOLLOW UP; HUMAN; INCIDENTAL FINDING; MALE; MEDICAL SOCIETY; MULTICENTER STUDY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SPLANCHNIC BLOOD FLOW; TREATMENT DURATION; TREATMENT OUTCOME; VEIN THROMBOSIS; CLINICAL TRIAL; DRUG EFFECTS; INCIDENCE; INTERNATIONAL COOPERATION; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REGISTER; SPLANCHNIC NERVE; SURVIVAL RATE;

ADULT; AGED; ANTICOAGULANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; SPLANCHNIC NERVES; SURVIVAL RATE; VENOUS THROMBOSIS;

EID: 84966559648     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(16)30020-5     Document Type: Article

References (27)

1. 1 De Stefano, V, Martinelli, I, Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 5 (2010), 487–494.
2. 2 Thatipelli, MR, McBane, RD, Hodge, DO, Wysokinski, WE, Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 8 (2010), 200–205.
3. 3 Ageno, W, Squizzato, A, Togna, A, et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost 10 (2012), 158–160.
4. 4 Ageno, W, Riva, N, Schulman, S, et al., IRSVT study group. Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost 40 (2014), 99–105.
5. 5 Dentali, F, Ageno, W, Becattini, C, et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res 125 (2010), 518–522.
6. 6 O'Connell, C, How I treat incidental pulmonary embolism. Blood 125 (2015), 1877–1882.
7. 7 Kearon, C, Akl, EA, Comerota, AJ, et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012), e419S–e494S.
8. 8 de Franchis, R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 63 (2015), 743–752.
9. 9 Ageno, W, Riva, N, Schulman, S, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med 175 (2015), 1474–1480.
10. 10 von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC, Vandenbroucke, JP, STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147 (2007), 573–577.
11. 11 Schulman, S, Kearon, C, for the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3 (2005), 692–694.
12. 12 Moons, KG, Kengne, AP, Woodward, M, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 98 (2012), 683–690.
13. 13 De Stefano, V, Qi, X, Betti, S, Rossi, E, Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost 115 (2016), 240–249.
14. 14 Singh, R, Sousou, T, Mohile, S, Khorana, AA, High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost 8 (2010), 1879–1881.
15. 15 Di Nisio, M, Ferrante, N, De Tursi, M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 104 (2010), 1049–1054.
16. 16 O'Connell, C, Razavi, P, Ghalichi, M, et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost 9 (2011), 305–311.
17. 17 den Exter, PL, Hooijer, J, Dekkers, OM, Huisman, MV, Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 29 (2011), 2405–2409.
18. 18 Søgaard, KK, Farkas, DK, Pedersen, L, Sørensen, HT, Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival. Blood 126 (2015), 957–963.
19. 19 Amitrano, L, Guardascione, MA, Brancaccio, V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 40 (2004), 736–741.
20. 20 Qi, X, De Stefano, V, Li, H, Dai, J, Guo, X, Fan, D, Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med 26 (2015), 23–29.
21. 21 Delgado, MG, Seijo, S, Yepes, I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 10 (2012), 776–783.
22. 22 Di Nisio, M, Lee, AY, Carrier, M, Liebman, HA, Khorana, AA, Subcommittee on Haemostasis and Malignancy. Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 13 (2015), 880–883.
23. 23 Condat, B, Pessione, F, Hillaire, S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 120 (2001), 490–497.
24. 24 Spaander, MC, Hoekstra, J, Hansen, BE, Van Buuren, HR, Leebeek, FW, Janssen, HL, Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost 11 (2013), 452–459.
25. 25 Plessier, A, Darwish-Murad, S, Hernandez-Guerra, M, et al., European Network for Vascular Disorders of the Liver (EN-Vie). Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 51 (2010), 210–218.
26. 26 Lisman, T, Porte, RJ, Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 116 (2010), 878–885.
27. 27 Riva, N, Ageno, W, Poli, D, et al. Recurrent thrombotic events after discontinuation of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter retrospective cohort study. Gastroenterol Res Pract, 2015, 2015, 620217.